TAKESHI MASUDA

Last Updated :2024/04/03

Affiliations, Positions
Hiroshima University Hospital, Assistant Professor
E-mail
ta-masudahiroshima-u.ac.jp
Self-introduction
Respiratry medicine, Lung cancer

Basic Information

Major Professional Backgrounds

  • 2013/04/01, 2014/03/31, Hiroshima University Hospital, Clinical Fellow
  • 2014/04/01, Hiroshima University Hospital, Assistant Professor

Academic Degrees

  • Doctor of Philosophy in Medical Science, Hiroshima University

In Charge of Primary Major Programs

  • Medicine

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Respiratory organ internal medicine
  • Medicine,dentistry, and pharmacy;Clinical internal medicine;General internal medicine (including psychosomatic medicine)

Research Keywords

  • Respiratory Internal Medicine
  • Clinical Oncology
  • Lung cancer

Educational Activity

Course in Charge

  1. 2024, Undergraduate Education, Year, Clinical diagnosis and treatment I
  2. 2024, Undergraduate Education, Intensive, Practice of Medicine I
  3. 2024, Undergraduate Education, Intensive, Practice of Medicine II
  4. 2024, Undergraduate Education, First Semester, Internal Medicine II
  5. 2024, Graduate Education (Master's Program) , Second Semester, General Clinical Medicine and Dentistry
  6. 2024, Graduate Education (Doctoral Program) , 1Term, Practice of Oncology

Research Activities

Academic Papers

  1. Usefulness of Quantification and Serial Monitoring of Fine Crackles for Early Detection of Treatment-related Lung Injury: A Report of Two Cases, Intern Med., 2023
  2. Exhaled Nitric Oxide and Olfactory Dysfunction in Patients with Asthma: Association with Chronic Rhinosinusitis, Medicina, 2023
  3. Nestin and Notch3 collaboratively regulate angiogenesis, collagen production, and endothelial-mesenchymal transition in lung endothelial cells, Cell Commun Signal, 2023
  4. Intestinal overgrowth of Candida albicans exacerbates bleomycin-induced pulmonary fibrosis in mice with dysbiosis, J Pathol., 2023
  5. Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L, Cancer Medicine, 2023
  6. Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer, Scientific Reports, 2023
  7. Effect of Dupilumab in a Patient With Severe Asthma Complicated With Recurrent Anaphylaxis: A Case Report, JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 33(3), 230-232, 2023
    Link to Paper Search Results by DOI
  8. Clinical characteristics of extrapulmonary nontuberculous mycobacteria infections in comparison with pulmonary infections: A single-center, retrospective study in Japan, JOURNAL OF INFECTION AND CHEMOTHERAPY, 29(9), 875-881, 202309
    Link to Paper Search Results by DOI
  9. Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility, JAMA NETWORK OPEN, 6(2), 202302
    Link to Paper Search Results by DOI
  10. Prediction model for patient prognosis in idiopathic pulmonary fibrosis using hybrid radiomics analysis, Diagn Interv Imaging, 2022
  11. A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC, JTO Clinical and Research Reports, 3(2), 2022
  12. Serum and bronchoalveolar lavage fluid levels of soluble B7H3 in patients with interstitial lung diseases, RESPIRATORY MEDICINE, 212, 202306
    Link to Paper Search Results by DOI
  13. Predictive value of serum high-mobility group box 1 levels for checkpoint inhibitor pneumonitis, RESPIROLOGY, 28(4), 380-388, 202304
    Link to Paper Search Results by DOI
  14. Preserved ratio impaired spirometry with or without restrictive spirometric abnormality, SCIENTIFIC REPORTS, 13(1), 20230220
    Link to Paper Search Results by DOI
  15. Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers, Adv Clin Chem ., 112, 2023
  16. Peak expiratory flow, but not tongue pressure, can predict pneumonia development in older adults, Eur Geriatr Med ., 14(1), 211-217, 2023
  17. Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial-Mesenchymal Transition, Cancers (Basel) ., 15(4), 2023
  18. Pre-Existing Interstitial Lung Abnormalities Are Independent Risk Factors for Interstitial Lung Disease during Durvalumab Treatment after Chemoradiotherapy in Patients with Locally Advanced Non-Small-Cell Lung Cancer, CANCERS, 14(24), 202212
    Link to Paper Search Results by DOI
  19. Association of the RAGE/RAGE-ligand axis with interstitial lung disease and its acute exacerbation, RESPIRATORY INVESTIGATION, 60(4), 531-542, 202207
    Link to Paper Search Results by DOI
  20. Association Between Patient Preference for Inhaler Medications and Asthma Outcomes, JOURNAL OF ASTHMA AND ALLERGY, 15, 1539-1547, 2022
    Link to Paper Search Results by DOI
  21. Dupilumab as an adjunct treatment for a patient with steroid-dependent immunoglobulin G4-related disease complicated by asthma: a case report, JOURNAL OF ASTHMA, 59(12), 2395-2401, 20221110
    Link to Paper Search Results by DOI
  22. Predictive role of circulatory levels of high-mobility group box 1 for radiation pneumonitis in patients with non-small cell lung cancer treated with definitive thoracic radiotherapy, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 27(11), 1698-1705, 202211
    Link to Paper Search Results by DOI
  23. Pneumonia and Meningoencephalitis Due to Varicella-zoster Virus Reinfection and Epstein-Barr Virus Reactivation in a Patient with Rheumatoid Arthritis, INTERNAL MEDICINE, 61(19), 2961-2965, 2022
    Link to Paper Search Results by DOI
  24. A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study, J Hematol Oncol ., 2022
  25. Incidence of venous thromboembolism in advanced lung cancer and efficacy and safety of direct oral anticoagulants: a multicenter, prospective, observational study (Rising-VTE/NEJ037 study), THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 14, 202207
    Link to Paper Search Results by DOI
  26. Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer, BMC PULMONARY MEDICINE, 22(1), 20220630
    Link to Paper Search Results by DOI
  27. Vocal cord dysfunction detected by a three-dimensional image of dynamic change in respiratory resistance in a patient with difficult-to-treat asthma: a case report, JOURNAL OF ASTHMA, 59(6), 1157-1161, 20220603
    Link to Paper Search Results by DOI
  28. Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1, THORACIC CANCER, 13(11), 1611-1618, 202206
    Link to Paper Search Results by DOI
  29. Tolerability and efficacy of IMpower133 regimen modified for dialysis patients with extensive-stage small cell lung cancer: Two case reports, THORACIC CANCER, 12(21), 2956-2960, 202111
    Link to Paper Search Results by DOI
  30. A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study, J Hematol Oncol ., 2022
  31. A Case of Pneumonia and Meningoencephalitis Due to Varicella-zoster Virus Reinfection and Epstein-Barr Virus Reactivation in a Patient with Rheumatoid Arthritis., Intern Med., 2022
  32. Primary Pulmonary Mucosa-associated Lymphoid Tissue Lymphoma with the High Expression of IgG4., Intern Med., 2022
  33. Pulmonary Alveolar Proteinosis with Severe Respiratory Failure Improved by Segmental Lung Lavage with Fiberoptic Bronchoscopy under General Anesthesia, INTERNAL MEDICINE, 61(3), 389-393, 2022
    Link to Paper Search Results by DOI
  34. Pneumatosis Intestinalis following Radiation Esophagitis during Chemoradiotherapy for Lung Cancer: A Case Report, CASE REPORTS IN ONCOLOGY, 14(3), 1454-1459, 2021
    Link to Paper Search Results by DOI
  35. Accelerated decline in lung function in adults with a history of remitted childhood asthma, EUROPEAN RESPIRATORY JOURNAL, 59(1), 20220101
    Link to Paper Search Results by DOI
  36. First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations, THORACIC CANCER, 13(5), 771-774, 202203
    Link to Paper Search Results by DOI
  37. SK-216, an Inhibitor of Plasminogen Activator Inhibitor-1, Limits Tumor Progression and Angiogenesis, MOLECULAR CANCER THERAPEUTICS, 12(11), 2378-2388, 201311
    Link to Paper Search Results by DOI
  38. MT95-4, a fully humanized antibody raised against aminopeptidase N, reduces tumor progression in a mouse model, CANCER SCIENCE, 106(7), 921-928, 201507
    Link to Paper Search Results by DOI
  39. Histological Quantification of Gene Silencing by Intratracheal Administration of Dry Powdered Small-Interfering RNA/Chitosan Complexes in the Murine Lung, PHARMACEUTICAL RESEARCH, 32(12), 3877-3885, 201512
    Link to Paper Search Results by DOI
  40. Inhibition of Plasminogen Activator Inhibitor-1 Attenuates Transforming Growth Factor-beta-Dependent Epithelial Mesenchymal Transition and Differentiation of Fibroblasts to Myofibroblasts, PLOS ONE, 11(2), 20160209
    Link to Paper Search Results by DOI
  41. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy., Cancer chemotherapy and pharmacology, 67(6), 1465-1469, 2011
  42. Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis, DISEASE MARKERS, 20160517
    Link to Paper Search Results by DOI
  43. Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma, CANCER RESEARCH, 76(11), 3285-3294, 20160601
    Link to Paper Search Results by DOI
  44. Two Cases of Lung Cancer with Carcinomatous Meningitis in Which Erlotinib Was Effective After Gefitinib Therapy, 49, 203-213, 2009
  45. Suplatast tosilate protects the lung against hyperoxic lung injury by scavenging hydroxyl radicals, FREE RADICAL BIOLOGY AND MEDICINE, 106, 1-9, 201705
    Link to Paper Search Results by DOI
  46. Chronic Intestinal Pseudo-obstruction and Orthostatic Hypotension Associated with Small Cell Lung Cancer that Improved with Tumor Reduction after Chemoradiotherapy, INTERNAL MEDICINE, 56(19), 2627-2631, 201710
    Link to Paper Search Results by DOI
  47. Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis., Internal Medicine, 11, 201712
  48. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer., Cancer Chemother Pharmacology, 201711
  49. Aminopeptidase N/CD13 as a Potential Therapeutic Target in Malignant Pleural Mesothelioma., Eur Respir J, 20180308
  50. AGER rs2070600 polymorphism elevates neutrophil-lymphocyte ratio and mortality in metastatic lung adenocarcinoma, Oncotarget, 55(8), 94382-94392, 20171010
  51. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma., Lung Cancer, 119, 21-24, 2018
  52. Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study, IN VIVO, 32(5), 1155-1160, 201800
    Link to Paper Search Results by DOI
  53. Intratracheal Administration of siRNA Dry Powder Targeting Vascular Endothelial Growth Factor Inhibits Lung Tumor Growth in Mice, MOLECULAR THERAPY-NUCLEIC ACIDS, 12, 698-706, 20180907
    Link to Paper Search Results by DOI
  54. Plasminogen activator inhibitor-1 serves an important role in radiation-induced pulmonary fibrosis, EXPERIMENTAL AND THERAPEUTIC MEDICINE, 16(4), 3070-3076, 201810
    Link to Paper Search Results by DOI
  55. Alternate-day administration of S-1 for elderly patients with advanced non-small-cell lung carcinoma: A prospective feasibility study., Mol Clin Oncol., 9(5), 539-534, 201811
  56. Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study, BMC cancer, 18(1), 1231, 20181210
  57. Serial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody A retrospective cohort study, MEDICINE, 97(49), 201812
    Link to Paper Search Results by DOI
  58. Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1, CANCER LETTERS, 442, 31-39, 201902
    Link to Paper Search Results by DOI
  59. High preoperative C-reactive protein level is a risk factor for acute exacerbation of interstitial lung disease after non-pulmonary surgery, MEDICINE, 98(5), e14296, 201902
    Link to Paper Search Results by DOI
  60. Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma A case report, MEDICINE, 98(12), e14821, 201903
    Link to Paper Search Results by DOI
  61. Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts, JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 23(4), 2984-2994, 201904
    Link to Paper Search Results by DOI
  62. Performance Status Is a Risk Factor for Depression before the Diagnosis of Lung Cancer Patients, INTERNAL MEDICINE, 58(7), 915-920, 201904
    Link to Paper Search Results by DOI
  63. Suplatast tosilate reduces radiation-induced lung injury in mice through suppression of oxidative stress, FREE RADICAL BIOLOGY AND MEDICINE, 136, 52-59, 20190520
    Link to Paper Search Results by DOI
  64. A Case of Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis, Internal Medicine, 58(21), 3129-3131
  65. Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumonia, RESPIRATORY MEDICINE, 152, 44-50, 201906
    Link to Paper Search Results by DOI
  66. A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY), CHEST, 156(2), 357-366, 201908
    Link to Paper Search Results by DOI
  67. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer, RESPIRATORY INVESTIGATION, 57(5), 451-459, 201909
    Link to Paper Search Results by DOI
  68. C-C Motif Chemokine Ligand 15 May Be a Useful Biomarker for Predicting the Prognosis of Patients with Chronic Hypersensitivity Pneumonitis, RESPIRATION, 98(3), 212-220, 201909
    Link to Paper Search Results by DOI
  69. Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer, ANTICANCER RESEARCH, 39(10), 5725-5731, 201910
    Link to Paper Search Results by DOI
  70. Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC, JOURNAL OF THORACIC ONCOLOGY, 14(12), 2071-2083, 201912
    Link to Paper Search Results by DOI
  71. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 25(1), 74-81, 2020
    Link to Paper Search Results by DOI
  72. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan, LUNG CANCER, 140, 8-18, 202002
    Link to Paper Search Results by DOI
  73. Prospective, randomized, cross-over pilot study of the effects of Rikkunshito, a Japanese traditional herbal medicine, on anorexia and plasma-acylated ghrelin levels in lung cancer patients undergoing cisplatin-based chemotherapy, INVESTIGATIONAL NEW DRUGS, 38(2), 485-492, 202004
    Link to Paper Search Results by DOI
  74. Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer, JOURNAL OF THORACIC DISEASE, 12(3), 1079-1084, 202003
    Link to Paper Search Results by DOI
  75. Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis, RESPIROLOGY, 25(3), 275-280, 202003
    Link to Paper Search Results by DOI
  76. Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis, RESPIRATORY RESEARCH, 21(1), 20200611
    Link to Paper Search Results by DOI
  77. Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR), ESMO OPEN, 5(4), 202007
    Link to Paper Search Results by DOI
  78. Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease, RESPIRATORY MEDICINE, 172, 202010
    Link to Paper Search Results by DOI
  79. Extent of pulmonary fibrosis on high-resolution computed tomography is a prognostic factor in patients with pleuroparenchymal fibroelastosis, RESPIRATORY INVESTIGATION, 58(6), 465-472, 202011
    Link to Paper Search Results by DOI
  80. Coexisting TIF1 gamma-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1 gamma Antibody-positive Dermatomyositis, INTERNAL MEDICINE, 59(20), 2553-2558, 2020
    Link to Paper Search Results by DOI
  81. Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers, JAMA NETWORK OPEN, 3(11), 20201112
    Link to Paper Search Results by DOI
  82. Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non-small cell lung cancer, CANCER SCIENCE, 112(1), 369-379, 202101
    Link to Paper Search Results by DOI
  83. Correlations of forced oscillometric bronchodilator response with airway inflammation and disease duration in asthma, CLINICAL RESPIRATORY JOURNAL, 15(1), 48-55, 202101
    Link to Paper Search Results by DOI
  84. Two Cases of Cranial Nerve Metastasis Treated with Radiotherapy and Chemotherapy in Patients with Lung Adenocarcinoma, CASE REPORTS IN ONCOLOGY, 13(3), 1495-1500, 2020
    Link to Paper Search Results by DOI
  85. Alectinib-induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma, INTERNAL MEDICINE, 60(4), 611-615, 2021
    Link to Paper Search Results by DOI
  86. Concomitant emphysema might increase the false-negative rate of urinary antigen tests in patients with pneumococcal pneumonia: results from a retrospective study, EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 40(4), 871-877, 202104
    Link to Paper Search Results by DOI
  87. Autoantibody Positivity Is a Risk Factor for Chemotherapy-induced Exacerbation of Interstitial Pneumonia in Lung Cancer, ANTICANCER RESEARCH, 41(3), 1497-1506, 202103
    Link to Paper Search Results by DOI
  88. Pulmonary lymphangitic carcinomatosis from recurrent gastric cancer 19 years after primary resection: a case report, CLINICAL JOURNAL OF GASTROENTEROLOGY, 14(2), 484-488, 202104
    Link to Paper Search Results by DOI
  89. Pulmonary arteriovenous malformation exhibiting recanalization >10 years after coil embolization Two case reports, MEDICINE, 99(2), 202001
    Link to Paper Search Results by DOI
  90. Prognostic Significance of EGFR Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care Alone, ANTICANCER RESEARCH, 41(5), 2661-2667, 202105
    Link to Paper Search Results by DOI
  91. Predictive role of circulatory HMGB1 in postoperative acute exacerbation of interstitial lung disease in lung cancer patients, SCIENTIFIC REPORTS, 11(1), 20210512
    Link to Paper Search Results by DOI
  92. Risk factors associated with increased discontinuation rate of trimethoprim-sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study, PULMONARY PHARMACOLOGY & THERAPEUTICS, 67, 202104
    Link to Paper Search Results by DOI
  93. D-dimer can be a diagnostic marker for cisplatin-related aortic thrombosis A case report, MEDICINE, 100(7), 20210219
    Link to Paper Search Results by DOI
  94. A machine-learning based approach to quantify fine crackles in the diagnosis of interstitial pneumonia A proof-of-concept study, MEDICINE, 100(7), 20210219
    Link to Paper Search Results by DOI
  95. IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis, PLOS ONE, 16(6), 20210604
    Link to Paper Search Results by DOI
  96. Quantitative parameters of lymphocyte nuclear morphology in bronchoalveolar lavage fluid as novel biomarkers for sarcoidosis, ORPHANET JOURNAL OF RARE DISEASES, 16(1), 20210703
    Link to Paper Search Results by DOI
  97. Gemcitabine maintenance therapy after gemcitabine and platinum drug chemotherapy for naive stage IIIB/IV squamous cell lung cancer: a phase II study, ANTI-CANCER DRUGS, 32(7), 767-772, 202108
    Link to Paper Search Results by DOI
  98. Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activity, STEM CELL RESEARCH & THERAPY, 12(1), 20210823
    Link to Paper Search Results by DOI
  99. Human bone marrow-derived mesenchymal stromal cells cultured in serum-free media demonstrate enhanced antifibrotic abilities via prolonged survival and robust regulatory T cell induction in murine bleomycin-induced pulmonary fibrosis, STEM CELL RESEARCH & THERAPY, 12(1), 20210916
    Link to Paper Search Results by DOI
  100. Analysis of microRNA Expression in Liquid-Based Cytology Samples May Be Useful for Primary Lung Cancer Diagnosis, AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 156(4), 644-652, 202110
    Link to Paper Search Results by DOI
  101. Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 88(5), 857-865, 202111
    Link to Paper Search Results by DOI
  102. Efficacy of erlotinib and its effects on the quality of life of older patients with epidermal growth factor receptor-mutant non-small cell lung cancer: A prospective, multicenter, dose-modification study, GERIATRICS & GERONTOLOGY INTERNATIONAL, 21(10), 881-886, 202110
    Link to Paper Search Results by DOI
  103. Potential benefits of volumetric modulated arc therapy to reduce the incidence of >= grade 2 radiation pneumonitis in radiotherapy for locally advanced non-small cell lung cancer patients, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 51(12), 1729-1735, 202112
    Link to Paper Search Results by DOI

Invited Lecture, Oral Presentation, Poster Presentation

  1. A study of lung cancer cases participated in cancer genome medicine at our hospital, Sumii M, Namba M, Tokumo K, Yamauchi M*, Nakahara H*, Urabe Y*, Nelson HC*, Itamura R*, Motonaga M*, Sakamoto S, Yamaguchi K, Masuda T, Fujitaka K, Okamoto W*, Arihiro K*, Hiyama E*, Hattori N, Hinoi T*, Sugiyama K*, 2023/03, Without Invitation, Japanese
  2. The difference in predictive value for checkpoint inhibitor pneumonitis between serum and plasma levels of HMGB1, Yamaguchi K, Tanahashi H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N, 2023/03, Without Invitation, Japanese
  3. The significance of micro-EGFR T790M mutation on EGFR-TKI efficacy in patients with NSCLC: The WJOG13119L study., Sato Y*, Masuda T, Miura S*, Tachihara M*, Hosokawa S*, Nakamura A*, Miyawaki T*, Yoshimine K*, Mori M*, Shiraishi H*, Hamai K, Haratani K*, Maeda S*, Tabata E*, Kitagawa C*, Tanizaki J*, Imai T*, Yamamoto N*, Nakagawa K*, Hattori N, 2022 ASCO Annual Meeting, 2022/06, Without Invitation, English
  4. Phase 2 study of first-line pembrolizumab in elderly patients with non-small cell lung cancer expressing high PD-L1., Hamai K, Masuda T, Fujitaka K, Suzuki T, Matsumoto N, Matsumura M, Isoyama S, Ueno S, Mito M, Yamaguchi K, Sakamoto S, Kawano R*, Masuda K, Nishino R, Ishikawa N, Yamasaki M, Hattori N, 2022 ASCO Annual Meeting, 2022/06, Without Invitation, English
  5. Liquid biopsy detects genomic drivers in non-small cell lung cancer without EGFR mutations by single-plex testing: WJOG13620L, Hazama D*, Uemura T*, Kenmotsu H*, Meano K*, Wakuda K*, Teraoka S*, Kobe H*, Azuma K*, Yamaguchi T*, Masuda T, Yokoyama T*, Otsubo K*, Haratani K*, Hayakawa D*, Oki M*, Takemoto S*, Ozaki T*, Okabe T*, Hata A*, Hashimoto H*, Yamamoto N*, Nakagawa K*, 2022 World Conference of Lung Cancer, 2022/08, Without Invitation, English
  6. Pre-existing interstitial lung abnormalities are independent risk factors for interstitial lung disease during durvalumab treatment after chemoradiotherapy in patients with locally advanced non–small lung cancer., Daido W, Masuda T, Imano N, Matsumoto N, Shoda H, Hamai K, Iwamoto Y, Takayama Y, Mishima S, Matsumura M, Masuda K, Ueno S, Kawase S, Awaya Y, Nishimura Y, Shiota N, Ishikawa N, Yamasaki M, Kitaguchi S, Fujitaka K, Nagata Y, Hattori N, 2022 ASCO Annual Meeting, 2022/06, Without Invitation, English
  7. The associations between patients preference for inhaled medications and asthma control, Nakanishi Y, Iwamoto H, Miyamoto S, Nakao S, Higaki N, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Matsumoto N, Nakashima T, Onari Y, Fujitaka K, Haruta Y, Hamada H, Hozawa S, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11, Without Invitation, English
  8. A case of pulmonary alveolar proteinosis with severe respiratory failure improved by segmental lung lavage with fiberoptic bronchoscopy under general anesthesia, Matsumoto Y, Masuda T, Takahashi H, Hashimoto K, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Ohshimo S, Fujitaka K, Yamasaki M, Hamada M, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11, Without Invitation, English
  9. Clinical characteristics of Preserved Ratio Impaired Spirometry in Japan, Miura S, Iwamoto H, Omori K, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fujitaka K, Hamada H, Yokoyama A, Hattori N, 2021/11, Without Invitation, Japanese
  10. Current status and future challenges of lung cancer genome medicine at our hospital, Namba M, Tokumo K, Yamauchi M, Nakahara H, Urabe Y, Nelson HC, Teratani Y, Kobayashi R, Itamura R, Motonaga M, Sakamoto S, Yamaguchi K, Masuda T, Fujitaka K, Okamoto W, Arihiro K, Hiyama E, Hattori N, Hinoi T, Sugiyama K, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11, Without Invitation, Japanese
  11. Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activity, Takahashi H, Nakashima T, Masuda T, Namba M, Sakamoto S, Yamaguchi K, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N, 2021/11, Without Invitation, Japanese
  12. The role of circulatory high-mobility group box 1 for predicting checkpoint inhibitor pneumonitis caused by anti-PD-1/PD-L1 antibody monotherapy, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11, Without Invitation, English
  13. Autoantibody positivity is a risk factor for chemotherapy-induced exacerbation of interstitial pneumonia in lung cancer, Ito N, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N, 2021/11, Without Invitation, English
  14. Mesenchymal stem cells cultured in serum-free medium suppress murine bleomycin-induced pulmonary fibrosis by enhancing regulatory T cell induction, Takao S, Nakashima T, Masuda T, Namba M, Sakamoto S, Yamaguchi K, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Nakashima A, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11, Without Invitation, English
  15. Involvement of PAI-1 in acquired resistance to osimertinib in EGFR-mutated lung cancer via its association with EMT., Tokumo K, Masuda T, Sakamoto S, Fujitaka K, Hattori N., 2020/10, Without Invitation, Japanese
  16. Clinical significance of BIM deletion polymorphism on chemoradiotherapy in patients with non-small cell lung cancer, Wakabayashi Y, Masuda T, Sakamoto S, Fujitaka K, Hattori N., 2020/10, Without Invitation, English
  17. Prognostic significance of EGFR gene mutation in patients with EGFR mutated non-small cell lung cancer who receive best supportive care alone, Masuda T, Wakabayashi Y, Sakamoto S, Fujitaka K, Hamada H, Hattori N., 2020/10, Without Invitation, English
  18. Decline of lung function in adults with a history of childhood asthma, Miura S, Iwamoto H, Omori K, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fujitaka K, Hamada H, Yokoyama A*, Hattori N, JSA/WAO Joint Congress 2020, 2020/09, Without Invitation, English
  19. Real-world study of prescription pattern of inhaled corticosteroids in adult asthma, Nakanishi Y, Iwamoto H, Nakao S, Higaki N, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Matsumoto N, Nakashima T, Miyamoto S, Onari Y, Fujitaka K, Haruta Y, Hamada H, Hozawa S, Hattori N, JSA/WAO Joint Congress 2020, 2020/09, Without Invitation, English
  20. Correlations of forced oscillometric bronchodilator response with airway inflammation and disease duration in asthma, Higaki N, Iwamoto H, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fujitaka K, Hamada H, Hattori N, JSA/WAO Joint Congress 2020, 2020/09, Without Invitation, English
  21. Pivotal role of the HMGB1/sRAGE axis in drug-induced lung injury in advanced lung cancer with pre-existing interstitial lung disease, Nakao S, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N, 30th International Congress of the European Respiratory Society, 2020/09, Without Invitation, English
  22. IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis, Nakanishi Y, Horimasu Y, Yamaguchi K, Sakamoto S, Masuda T, Nakashima T, Miyamoto S, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N, 30th International Congress of the European Respiratory Society, 2020/09, Without Invitation, English
  23. Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis, Yamaguchi K, Iwamoto H, Mazur W*, Miura S, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N, 30th International Congress of the European Respiratory Society, 2020/09, Without Invitation, English
  24. Increased fraction of small round lymphocyte in BALF is a diagnostic indicator for sarcoidosis, Horimasu Y, Yamaguchi K, Sakamoto S, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N., 30th International Congress of the European Respiratory Society, 2020/09, Without Invitation, English
  25. Difference between pathogenic and inhibitory bacterial florae is associated with acute exacerbation of idiopathic pulmonary fibrosis, Ohshimo S, Nishi H*, Yamaguchi K, Horimasu Y, Masuda T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Kawaguchi H*, Bonella F*, Guzman J*, Costabel U*, Hattori N, Shime N, 30th International Congress of the European Respiratory Society, 2020/09, Without Invitation, English
  26. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-NSCLC cancers, Shimoji K, Masuda T, Nakanishi Y, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N, 2020 ASCO Annual Meeting, 2020/05, Without Invitation, English
  27. Clinical significance of BIM deletion polymorphism on chemoradiotherapy in patients with non-small cell lung cancer, Wakabayashi Y, Masuda T, Nakashima T, Fujitaka K, Yamaguchi K, Sakamoto S, Nishimura Y, Horimasu Y, Miyamoto S, Senoo T, IwamotoH, Ohshimo S, Hamada H, Hattori N, 2020 ASCO Annual Meeting, 2020/05, Without Invitation, English
  28. EGFR gene mutation is not a significant risk factor in patients with EGFR mutated non-small cell lung cancer who receive best supportive care alone, Masuda T, Wakabayashi Y, Shimoji K, Yamaguchi K, Sakamoto S, Nishimura Y, Horimasu Y, Nakashima T, Miyamoto S, Senoo T, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N., 2020 ASCO Annual Meeting, 2020/05, Without Invitation, English
  29. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer, Nakanishi Y, Masuda T, Sakamoto S, Yamaguchi K, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N., The 24th Congress of the Asian Pacific Society of Respirology (APSR 2019), 2019/11, Without Invitation, English
  30. The incidence and risk factors for acute exacerbation of interstitial lung disease after non-pulmonary surgery., Takao S, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N., The 24th Congress of the Asian Pacific Society of Respirology (APSR 2019), 2019/11, Without Invitation, English
  31. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer, Masuda T, Nakanishi Y, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N., The 24th Congress of the Asian Pacific Society of Respirology (APSR 2019), 2019/11/14, Without Invitation, English
  32. Clinical Utility of BALF CCL15 as a prognostic biomarker for Chronic Hypersensitivity Pneumonitis, Watanabe M,Horimasu Y, Iwamoto H, Yamaguchi K, Sakamoto S, Masuda T, Nakashima T, Miyamoto S, Ohshimo S, Fujitaka K, Hamada H, Kohno N, Hattori N., European Respiratory Society International Congress 2019, 2019/09/28, Without Invitation, Japanese
  33. Fine crackles quantitative value can help the diagnosis of interstitial lung diseases – Clinical utility of the innovative analyzing system of respiratory sounds, Horimasu Y, Ohshimo S, Yamaguchi K, Sakamoto S, Masuda T, Nakashima T, Miyamoto S, Iwamoto H, Sadamori T*, Fujitaka K, Hamada H, Shime N, Hattori N., 2019/09/28, Without Invitation, English
  34. Serum high mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis, Yamaguchi K, Iwamoto H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N., European Respiratory Society International Congress 2019, 2019/09/28, Without Invitation, English
  35. SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis., Takeshi Masuda, Noboru Hattori, Tadashi Senoo, American Thoracic Society International Conference, San Diego, USA, 2014., 2014, Without Invitation, English
  36. SK-216, an inhibitor of plasminogen activator inhibitor-1, inhibits tumor growth in a mouse model of pleural mesothelioma., Yusuke Takayama, Noboru Hattori, Hironobu Hamada, Takeshi Masuda, American Thoracic Society International Conference, San Diego, USA, 2014., 2014, Without Invitation, English
  37. Gene expression profiles of idiopathic interstitial pneumonitis: Molecular signatures of pulmonary fibrosis, Nobuhisa Ishikawa, Takeshi Masuda, Yasushi Horimasu, Noboru Hattori, Shinichiro Ohshimo, Nobuoki Kohno, 2014, Without Invitation, English
  38. SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis., Takeshi Masuda, Noboru Hattori, Tadashi Senoo, 2014, Without Invitation, English
  39. SK-216, an inhibitor of plasminogen activator inhibitor-1, inhibits tumor growth in a mouse model of pleural mesothelioma., Yusuke Takayama, Noboru Hattori, Hironobu Hamada, Takeshi Masuda, 2014, Without Invitation, English
  40. Anti-tumor Effect of MT95-4, a Fully Humanized Anti-Aminopeptidase N Monoclonal Antibody, on Tumor Progression in an Animal Model of Malignant Pleural Mesothelioma., Takahiko Otsuki, Noboru Hattori, Hironobu Hamada, Horimasu Yasushi, Takeshi Masuda, Taku Nakashima, Iwamoto Hiroshi, Kazunori Fujitaka, Nobuoki Kohno, American Thoracic Society International Conference 2016, 2016/05/13, Without Invitation, English
  41. PAI-1 plays an important role in radiatiopn-induced pulmonary fibrosis, Sachiko Shioya, Noboru Hattori, Takeshi Masuda, Tadashi Senoo, Taku Nakashima, Hiroshi Iwamoto, Kazunori Fujitaka, Nobuoki Kohno, American Thoracic Society International Conference 2016, 2016/05/13, Without Invitation, English
  42. PAI-1 plays an important role in lung cancer progression through the association with differentiation of cancer-associated fibroblasts to myofibroblasts, Takeshi Masuda, Noboru Hattori, Yasushi Horimasu, Kazunori Fujitaka, Hironobu Hamada, American Thoracic Society　International Conference 2016, 2016/05/13, Without Invitation, Japanese
  43. Decreased circulatory receptor for advanced glycation end-products is associated with poorer survival in patients with idiopathic pulmonary fibrosis, Kakuhiro Yamaguchi, Hiroshi Iwamoto, Yasushi Horimasu, Takeshi Masuda, Taku Nakashima, Shintaro Miyamoto, Shinichiro Ohshimo, Kazunori Fujitaka, Noboru Hattori, Witold Mazur, Nobuoki Kohno., 2016/04/10, Without Invitation, English
  44. PAI-1 plays an important role in lung cancer progression through the association with differentiation of cancer-associated fibroblasts to myofibroblasts, Takeshi Masuda, Noboru Hattori, Yasushi Horimasu, Kazunori Fujitaka, Hironobu Hamada, 2016/10/06, Without Invitation, English
  45. Airway reversibility assessed by oscillometry in patients with asthma, Higaki N, Iwamoto H, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fjitaka K, Hamada H, Hattori N, ERS Milan 2017 International Congress, 2017/09/09, Without Invitation, English, European Respiratory Society, Milan, Italy
  46. PAI-1 Influences the Effectiveness of Chemotherapy Through Its Association with Apoptosis in Cancer-Associated Myofibroblasts, T. Masuda. T. Nakashima , M. Namba , K. Yamaguchi , S. Sakamoto , Y. Horimasu , S. Miyamoto , H. Iwamoto , K. Fujitaka , H. Hamada , N. Hatttori, American Thoracic Society 2018 International Conference", 2018/05/18, Without Invitation, English
  47. Vascular Endothelial Growth Factor Knockdown by Intratracheal Administration of Small-Interfering RNA Dry Powder Inhibits Tumor Growth in a Mouse Lung Metastasis Model, K. Miyata. Y. Horimasu , T. Masuda , S. Miyamoto , T. Nakashima , H. Iwamoto , K. Fujitaka , H. Hamada , N. Hattori, American Thoracic Society 2018 International Conference, 2018/05/18, Without Invitation, English, Sandiego, USA
  48. Extent of the Honeycombing Area and the Presence of Traction Bronchiectasis Are Risk Factors for Poorer Prognosis in Patients with Pleuroparenchymal Fibroelastosis, M. Namba. T. Masuda , K. Yamaguchi , S. Sakamoto , Y. Horimasu , S. Miyamoto , T. Nakashima , H. Iwamoto , S. Ohshimo , K. Fujitaka , H. Hamada , N. Hattori, American Thoracic Society 2018 International Conference, 2018/05/18, Without Invitation, English, Sandiego, USA
  49. IPFの遺伝子素因　MUC5B遺伝子多型を中心に, 堀益 靖, 山口 覚博, 坂本 信二郎, 益田 武, 中島 拓, 岩本 博志, 藤高 一慶, 服部 登, 第58回日本呼吸器学会学術講演会, 2018/04/27, Without Invitation, Japanese
  50. Pleuroparenchymal fibroelastosisと特発性肺線維症の臨床的相違点の検討, 難波将史，益田武，山口覚博，堀益靖，宮本真太郎，中島拓，岩本博志，藤高一慶，濱田泰伸，服部登, 2018/04/13, Without Invitation, Japanese

Awards

  1. 2019, Interstitial Lung Disease Assembly Education Awardee, APSR, Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer

External Funds

Acceptance Results of Competitive Funds

  1. 2023, 2026
  2. 2021/03, 2023/02
  3. 2020, 2021
  4. 2019, 2019
  5. KAKENHI, 2018, 2020
  6. KAKENHI, 2015, 2017
    Permalink
  7. 2018, 2019
  8. 2015, 2016

Social Activities

History as Peer Reviews of Academic Papers

  1. 2023, Internal Medicine, Others
  2. 2023, Journal of Thoracic Disease, Others
  3. 2023, Cancers, Others
  4. 2023, Cancers, Others
  5. 2023, BMC pulmonary medicine, Others
  6. 2023, BMC cancer, Others
  7. 2023, Scientific Reports, Others
  8. 2022, Journal of Cancer Research and Clinical Oncology, Others
  9. 2022, Cancers, Others
  10. 2022, BMC cancer, Others
  11. 2022, BMC pulmonary medicine, Others
  12. 2021, Respiratory Investigation, Others
  13. 2021, Internal Medicine, Others
  14. 2021, Respiratory Investigation, Others
  15. 2021, Journal of Thoracic Disease, Others
  16. 2020, Cancer Management and Research, Others
  17. 2020, Journal of Thoracic Disease, Others, 1
  18. 2018, Journal of thoracic disease
  19. 2019, Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, Others
  20. 2018, Japanese Journal of Clinical Oncology
  21. 2020, Histology and Histopathology, Others
  22. 2020, Respiratory Investigation, Others
  23. 2019, BMC Research Notes, Others
  24. 2019, Journal of Thoracic Disease, Others
  25. 2016, Oncotarget, Others
  26. 2018, 気管支学, Others
  27. 2018, Scientific Reports, Others
  28. 2019, OncoTargets and Therapy, Others
  29. 2019, Evidence-Based Complementary and Alternative Medicine, Others
  30. 2013, Cancer Science, Others
  31. 2014, Respiratory Investigation, Others
  32. 2014, Internal Medicine, Others
  33. 2014, Japanese Journal of Clinical Oncology, Others
  34. 2014, Annals of Oncology, Others
  35. 2014, Annals of Oncology
  36. 2015, PLOS ONE, Others
  37. 2016, Oncotarget, Others
  38. 2016, Internal medicine, Others